Background & Aims HMG-CoA-reductase-inhibitors (statins) have been shown to interfere with HCV replication in vitro. We investigated the mechanism, requirements and contribution of heme oxygenase-1(HO-1)-induction by statins to interference with HCV replication. Methods HO-1-induction by fluva-, simva-, rosuva-, atorva- or pravastatin was correlated to HCV replication, using non-infectious replicon systems as well as the infectious cell culture system. The mechanism of HO-1-induction by statins as well as its relevance for interference with HCV replication was investigated using transient or permanent knockdown cell lines. Polyacrylamide(PAA) gels of different density degrees or the Rho-kinase-inhibitor Hydroxyfasudil were used in order to mimic matrix conditions corresponding to normal versus fibrotic liver tissue. Results All statins used, except pravastatin, decreased HCV replication and induced HO-1 expression, as well as interferon response in vitro. HO-1-induction was mediated by reduction of Bach1 expression and induction of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) cofactor Krueppel-like factor 2 (KLF2). Knockdown of KLF2 or HO-1 abrogated effects of statins on HCV replication. HO-1-induction and anti-viral effects of statins were more pronounced under cell culture conditions mimicking advanced stages of liver disease. Conclusions Statin-mediated effects on HCV replication seem to require HO-1-induction, which is more pronounced in a microenvironment resembling fibrotic liver tissue. This implicates that certain statins might be especially useful to support HCV therapy of patients at advanced stages of liver disease.
References
[1]
Tang H, Grisé H (2009) Cellular and molecular biology of HCV infection and hepatitis. Clin Sci 117: 49–65. doi: 10.1042/cs20080631
[2]
Blonski W, Reddy KR (2008) Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 12: 661–674. doi: 10.1016/j.cld.2008.03.007
[3]
Sherman KE, Flamm SL, Nezam HA, Nelson DR, Sulkowski MS, et al. (2011) Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. N Engl J Med 365: 1014–1024. doi: 10.1056/nejmoa1014463
[4]
Halfon P, Locarnini S (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192–206. Review
[5]
Kelvin KW, Chan AMO, Lillian LS (2003) The Statins as Anticancer Agents. Clin Cancer Res 9: 10–19.
[6]
Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, et al. (2012) Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28: 1077–1083. doi: 10.1055/s-0031-1295979
[7]
Ramachandran C, Patil RV, Combrink K, Sharif NA, Sirnivas SP (2011) Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells. Mol Vis 17: 1877–1890.
[8]
Giguère JF, Tremblay MJ (2004) Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78: 12062–12065. doi: 10.1128/jvi.78.21.12062-12065.2004
[9]
Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, et al. (2008) Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 10: 471–480. doi: 10.1016/j.micinf.2008.01.009
[10]
Liu Z, Guo Z, Wang G, Zhang D, He H, et al. (2009) Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 38: 215–223. doi: 10.1016/j.ejps.2009.07.004
[11]
Bader T, Fazili J, Madhoun M, Aston C, Hughes D, et al. (2008) Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103: 1383–1389.
[12]
Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, et al. (2009) An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52: 43–48. doi: 10.1159/000213504
[13]
O'Leary JG, Chan JL, McMahon CM, Chung RT (2007) Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 45: 895–898. doi: 10.1002/hep.21554
[14]
Forde KA, Law C, O'Flynn R, Kaplan DE (2010) Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 15: 5020–5027. doi: 10.3748/wjg.15.5020
[15]
Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, et al. (2010) Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother 65: 735–740. doi: 10.1093/jac/dkq002
[16]
Ikeda M, Abe K, Yamada M, Dansako H, Naka K, et al. (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44: 117–125. doi: 10.1002/hep.21232
[17]
Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, et al. (2004) The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 37: 2064–2071. doi: 10.1016/j.freeradbiomed.2004.09.009
[18]
Lee T, Chang C, Zhu Y, Shyy J (2004) Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110: 1296–1302. doi: 10.1161/01.cir.0000140694.67251.9c
[19]
Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, et al. (2007) Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170: 1192–1199. doi: 10.2353/ajpath.2007.060782
[20]
Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL (2007) Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133: 1166–1174. doi: 10.1053/j.gastro.2007.08.002
[21]
Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, et al. (2010) Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52: 1897–1905. doi: 10.1002/hep.23921
[22]
Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, et al. (2010) The heme oxygenase 1 product biliverdin interferes with HCV replication by increasing anti-viral interferon response. Hepatology 51: 398–404. doi: 10.1002/hep.23339
[23]
Zhu Z, Wilson AT, Luxon BA, Brown KE, Mathahs MM, et al. (2010) Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52: 1897–1905. doi: 10.1002/hep.23921
[24]
Lohmann V, K？rner F, Koch J, Herian U, Theilmann L, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113. doi: 10.1126/science.285.5424.110
[25]
Frese M, Barth K, Kaul A, Lohmann V, Schwarzle V, et al. (2003) Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol 84: 1253–1259. doi: 10.1099/vir.0.18997-0
[26]
Neuvonen PJ (2010) Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11: : 323–332, 2010. Review
[27]
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283–1298. doi: 10.1016/j.cell.2006.01.040
[28]
Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, et al. (2006) PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 80: 7995–8005. doi: 10.1128/jvi.00734-06
[29]
Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408–7413. doi: 10.1073/pnas.0504877103
[30]
Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, et al. (2007) Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 81: 5270–5283. doi: 10.1128/jvi.00032-07
[31]
Engler A, Bacakova L, Newman C, Hategan A, Griffin M, et al. (2004) Substrate compliance versus ligand density in cell on gel responses. Biophys J 86: 617–628. doi: 10.1016/s0006-3495(04)74140-5
[32]
Schrader J, Gordon-Walker TT, Aucott RL, Deemter M, Quaas A, et al. (2011) Matrix stiffness modulates proliferation, chemotherapeutic response and dormancy in hepatocellular carcinoma cells. Hepatology 53: 1192–1205. doi: 10.1002/hep.24108
[33]
Pelham RJ Jr, Wang Y (2007) Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci U S A 94: 13661–13665. doi: 10.1073/pnas.94.25.13661
[34]
Fledderus JO, Boon RA, Volger OL, Hurttila H, Yl？-Herttuala S, et al. (2008) KLF2 Primes the Antioxidant Transcription Factor Nrf2 for Activation in Endothelial cells. Arterioscler Thromb Vasc Biol. 28: 1339–1346. doi: 10.1161/atvbaha.108.165811
[35]
Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, et al. (2009) Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50: 6–16. doi: 10.1002/hep.22916
[36]
Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, et al. (2012) An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J Viral Hepat. 9: 615–22. doi: 10.1111/j.1365-2893.2011.01584.x
[37]
Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, et al. (2010) Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. J Antimicrob Chemother. 4: 735–40. doi: 10.1093/jac/dkq002
[38]
Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. (2013) Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study. PLoS ONE 8: e52828. doi: 10.1371/journal.pone.0052828
[39]
Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, et al. (2009) An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52: 43–48. doi: 10.1159/000213504
[40]
O'Leary JG, Chan JL, McMahon CM, Chung RT (2007) Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007 45: 895–898. doi: 10.1002/hep.21554
[41]
Forde KA, Law C, O'Flynn R, Kaplan DE (2009) Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009 15: 5020–5027. doi: 10.3748/wjg.15.5020
[42]
Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, et al. (2003) Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100: 15865–15870. doi: 10.1073/pnas.2237238100
[43]
Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9: 10–19.
[44]
Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Post-translational modification and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery 6: 541–555. doi: 10.1038/nrd2221
[45]
Charlton-Menys V, Durrington PN (2008) Human cholesterol metabolism and therapeutic molecules. Exp Physiol 93: 27–42. doi: 10.1113/expphysiol.2006.035147
[46]
Shan Y, Lambrecht RW, Ghaziani T, Donohue SE, Bonkovsky HL (2004) Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells. J Biol Chem 50: 51769–51774. doi: 10.1074/jbc.m409463200
[47]
Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, et al. (2010) Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51: 388–397. doi: 10.1002/hep.23340
[48]
Tandra S, Vuppalanchi R (2009) Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 11: 272–278. doi: 10.1007/s11936-009-0028-2
